genai / news / / Los Angeles Times
OpenAI is rolling out an early version of an artificial intelligence model designed to accelerate drug discovery.
OpenAI launched GPT-Rosalind, an AI model specifically built for life sciences research applications.
KEY POINTS
- GPT-Rosalind will first be available to select business customers, including Amgen, Moderna, and the Allen Institute.
- Shares of several drug discovery companies dropped sharply after OpenAI announced its new AI model.
- OpenAI has implemented high-precision flags in GPT-Rosalind to detect potential bioweapons-related activity.
COMPANIES
Summarized by Newsio from Los Angeles Times. How we summarize →